Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 2 (2005), Issue 5 (May)

1. Acute myeloid leukemia cell lines MOLM-17 and MOLM-18 derived from patient with advanced myelodysplastic syndromes.
   Leuk Res, 29(6): 701-10. [Abstract] [Full-text]
2. Analysis of HFE and TFR2 gene mutations in patients with acute leukemia.
   Leuk Res, 29(6): 661-4. [Abstract] [Full-text]
3. Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia.
   Leuk Res, 29(6): 653-9. [Abstract] [Full-text]
4. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
   Leuk Res, 29(6): 649-52. [Abstract] [Full-text]
5. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia.
   Leuk Res, 29(6): 617-23. [Abstract] [Full-text]
6. High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience.
   Leuk Res, 29(6): 609-15. [Abstract] [Full-text]
7. Microsatellite instability is not an uncommon finding in adult de novo acute myeloid leukemia.
   Ann Hematol, 84(6): 368-75. [Abstract] [Full-text]
8. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
   Ann Hematol, 84(6): 376-82. [Abstract] [Full-text]
9. Allogeneic versus autologous versus peripheral stem cell transplantation in CR1 pediatric AML patients: a single center experience.
   Pediatr Blood Cancer, 44(7): 654-9. [Abstract] [Full-text]
10. Genotype-dependent induction of transmissible chromosomal instability by gamma-radiation and the benzene metabolite hydroquinone.
    Cancer Res, 65(9): 3527-30. [Abstract] [Full-text]
11. Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts.
    Clin Cancer Res, 11(9): 3217-24. [Abstract] [Full-text]
12. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells.
    Blood, 105(10): 4043-50. [Abstract] [Full-text]
13. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect.
    Blood, 105(10): 4135-42. [Abstract] [Full-text]
14. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group.
    Bone Marrow Transplant, 35(10): 1011-8. [Abstract] [Full-text]
15. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
    Bone Marrow Transplant, 35(10): 965-70. [Abstract] [Full-text]
16. Haplotype mismatched transplantation using high doses of peripheral blood CD34+ cells together with stratified conditioning regimens for high-risk adult acute myeloid leukemia patients: a pilot study in a single Korean institution.
    Bone Marrow Transplant, 35(10): 959-64. [Abstract] [Full-text]
17. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Cancer, 103(10): 2082-90. [Abstract] [Full-text]
18. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
    Cancer, 103(10): 1985-95. [Abstract] [Full-text]
19. Molecular signature of retinoic acid treatment in acute promyelocytic leukemia.
    Oncogene, 24(20): 3358-68. [Abstract] [Full-text]
20. Successful non-T-cell-depleted HLA-haploidentical 3-loci mismatched bone marrow transplantation.
    Eur J Haematol, 74(6): 529-32. [Abstract] [Full-text]
21. Sequential organ failure predicts mortality of patients with a haematological malignancy needing intensive care.
    Eur J Haematol, 74(6): 511-6. [Abstract] [Full-text]
22. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile.
    Genes Chromosomes Cancer, 43(3): 227-38. [Abstract] [Full-text]
23. Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: population-based data.
    BMC Cancer, 5(1): 33. [Abstract] [Full-text]
24. Repeated sequences in CASPASE-5 and FANCD2 but not NF1 are targets for mutation in microsatellite-unstable acute leukemia/myelodysplastic syndrome.
    Mol Cancer Res, 3(5): 251-60. [Abstract] [Full-text]
25. Dominant and opportunistic leukemic clones: proposal for a pathogenesis-oriented classification in acute myeloid leukemia.
    Med Hypotheses, 65(1): 107-13. [Abstract] [Full-text]
26. A COMPASS in the voyage of defining the role of trithorax/MLL-containing complexes: linking leukemogensis to covalent modifications of chromatin.
    J Cell Biochem, 95(3): 429-36. [Abstract] [Full-text]
27. Two cases of acute myeloid leukemia with t(11;17) associated with varying morphology and immunophenotype: rearrangement of the MLL gene and a region proximal to the RARalpha gene.
    Cancer Genet Cytogenet, 159(2): 168-73. [Abstract] [Full-text]
28. Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia.
    Cancer Genet Cytogenet, 159(2): 129-36. [Abstract] [Full-text]
29. Point mutation in AML1 disrupts subnuclear targeting, prevents myeloid differentiation, and effects a transformation-like phenotype.
    Proc Natl Acad Sci U S A, 102(20): 7174-9. [Abstract] [Full-text]
30. Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells.
    Br J Cancer, 92(10): 1942-7. [Abstract] [Full-text]
31. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.
    Bone Marrow Transplant, 35(11): 1089-93. [Abstract] [Full-text]
32. Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development.
    Blood, 105(11): 4298-307. [Abstract] [Full-text]
33. AML1-FOG2 fusion protein in myelodysplasia.
    Blood, 105(11): 4523-6. [Abstract] [Full-text]
34. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.
    Blood, 105(11): 4215-22. [Abstract] [Full-text]
35. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.
    Blood, 105(11): 4163-9. [Abstract] [Full-text]
36. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older.
    J Clin Oncol, 23(15): 3439-46. [Abstract] [Full-text]
37. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
    J Clin Oncol, 23(15): 3404-11. [Abstract] [Full-text]
38. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
    J Clin Oncol, 23(15): 3447-54. [Abstract] [Full-text]
39. HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun.
    Exp Hematol, 33(6): 660-70. [Abstract] [Full-text]
40. The risk of developing second cancers among survivors of childhood soft tissue sarcoma.
    Cancer, 103(11): 2391-6. [Abstract] [Full-text]
41. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison.
    Leukemia, 19(6): 916-20. [Abstract] [Full-text]
42. Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era.
    Leukemia, 19(6): 965-70. [Abstract] [Full-text]
43. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
    Leukemia, 19(6): 930-5. [Abstract] [Full-text]
44. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients.
    Int J Hematol, 81(4): 349-51. [Abstract] [Full-text]
45. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples.
    Stem Cells, 23(6): 752-60. [Abstract] [Full-text]
46. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
    Cancer Immunol Immunother, 54(7): 685-93. [Abstract] [Full-text]
47. Podocalyxin: a marker of blasts in acute leukemia.
    Am J Clin Pathol, 124(1): 134-42. [Abstract] [Full-text]
48. Induction of leukemia-specific CD8+ cytotoxic t cells with autologous myeloid leukemic cells maturated with a fiber-modified adenovirus encoding TNF-alpha.
    Mol Ther, 11(6): 950-9. [Abstract] [Full-text]
49. Cytotoxic activity of new lanthanum (III) complexes of bis-coumarins.
    Eur J Med Chem, 40(6): 542-51. [Abstract] [Full-text]

© 2004-2010 Acute Myeloid Leukemia Research Today. All Rights Reserved.